Management of Activated Protein C Resistance in Pregnancy
For pregnant women with activated protein C resistance (APCR) and no prior VTE history, clinical surveillance is recommended during pregnancy, with postpartum prophylaxis reserved for those with a positive family history of VTE. 1
Risk Stratification Framework
The management approach depends critically on three factors:
- Prior VTE history (personal thrombotic events)
- Family history of VTE (first-degree relatives, especially if <50 years old)
- Additional thrombotic risk factors (obesity, immobility, pregnancy complications)
Antepartum Management
Women WITHOUT Prior VTE
No family history of VTE:
- Clinical surveillance only throughout pregnancy 1
- The 2018 ASH guidelines explicitly recommend against routine antepartum prophylaxis (conditional recommendation, very low certainty evidence) 1
With family history of VTE:
- Consider antepartum prophylaxis with prophylactic- or intermediate-dose LMWH 1
- Seek expert consultation, particularly for protein C or S deficiency 1
- The decision should weigh the family history strength (age of relative at thrombosis, number of affected relatives)
Women WITH Prior VTE
Low-risk recurrence (single VTE from transient non-pregnancy/non-estrogen trigger):
- Clinical vigilance antepartum rather than prophylaxis (Grade 2C) 2
Moderate-to-high risk recurrence (unprovoked VTE, pregnancy/estrogen-related VTE, or multiple prior VTE):
- Antepartum prophylaxis with prophylactic- or intermediate-dose LMWH (Grade 2C) 2
On long-term anticoagulation:
- Switch to adjusted-dose LMWH or 75% therapeutic dose LMWH throughout pregnancy (Grade 2C) 2
Postpartum Management
Women WITHOUT Prior VTE
No family history of VTE:
- Clinical surveillance only 1
- ASH guidelines recommend against routine postpartum prophylaxis (conditional recommendation) 1
With family history of VTE:
- Postpartum prophylaxis with prophylactic- or intermediate-dose LMWH for 6 weeks (Grade 2C) 1
- Alternative: vitamin K antagonists (warfarin) targeted at INR 2.0-3.0 for 6 weeks 1
With additional risk factors (≥2 of the following):
- BMI ≥30 kg/m² at first visit
- Smoking >10 cigarettes/day
- Preeclampsia
- Intrauterine growth restriction
- Placenta previa
- Emergency cesarean section
- Blood loss >1L or transfusion requirement
- Preterm delivery
- Stillbirth
- Maternal comorbidities (cardiac disease, SLE, sickle cell disease, inflammatory disease, varicose veins, gestational diabetes)
→ Prophylaxis for 6 weeks postpartum 1
Women WITH Prior VTE
All women with prior VTE:
- Postpartum prophylaxis for 6 weeks with prophylactic- or intermediate-dose LMWH or vitamin K antagonists (INR 2.0-3.0) (Grade 2B) 2
- Minimum total anticoagulation duration of 3 months if treating acute VTE 2
Practical Considerations
LMWH Dosing Around Delivery
- Discontinue LMWH at least 24 hours prior to planned induction, cesarean section, or neuraxial anesthesia (Grade 1B) 2
- This timing is critical to minimize bleeding risk while maintaining thromboprophylaxis
Cesarean Section-Specific Guidance
- Without additional risk factors: Early mobilization only (Grade 1B) 2
- With ≥1 major or ≥2 minor risk factors: Prophylactic LMWH or mechanical prophylaxis (elastic stockings/intermittent pneumatic compression) while hospitalized (Grade 2B) 2
- Very high risk with multiple persistent factors: Combine LMWH with mechanical prophylaxis (Grade 2C) 2
Important Caveats
Acquired vs. Inherited APCR: The evidence primarily addresses inherited thrombophilias. Pregnancy itself causes acquired APCR 3, which complicates interpretation. Testing should ideally be performed remote from pregnancy (>8 weeks postpartum) for accurate baseline assessment.
Factor V Leiden vs. Non-FVL APCR: Most guidelines focus on Factor V Leiden. Research shows non-FVL APCR may have different pregnancy risks 4, including increased second-trimester fetal loss but not necessarily increased VTE risk. However, current guidelines do not differentiate management based on this distinction.
Protein C/S Deficiency: These conditions receive identical recommendations to other thrombophilias in the 2018 ASH guidelines 1, though older ACCP guidelines suggested considering expert consultation 2.
Guideline Strength: The 2018 ASH guidelines 1 represent the most recent high-quality evidence and should take precedence over the 2012 ACCP guidelines [2-2], though recommendations are largely concordant.